[
  {
    "objectID": "posts.html",
    "href": "posts.html",
    "title": "My Blog",
    "section": "",
    "text": "Some good sentences\n\n\n\nsentences\n\n\n\nJust my point of view\n\n\n\nKang Wu\n\n\nJul 20, 2025\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe biological-relevant questions\n\n\n\nMiscellany\n\n\n\nThe routine questions I donâ€™t know and the answers\n\n\n\nKang Wu\n\n\nJul 8, 2025\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "posts/maybe_good_sentences/index.html",
    "href": "posts/maybe_good_sentences/index.html",
    "title": "Some good sentences",
    "section": "",
    "text": "Antibody function is governed not only by antigen specificity, conferred by the antigen-binding (Fab) domain to neutralize pathogens but also by the antibody constant (Fc) domain, which recruits complement and engages Fc receptors (FcRs) on the surface of immune cells.\n\nImmunity. 2025. PMID: 40449485\n\nAny given MHC molecule can bind numerous different peptides, and some peptide can bind to several different MHC molecules. Because of this broad specificity, the binding between a peptide and an MHC molecule is often referred to as â€œpromiscuousâ€.\n\nKuby immunology 2018 p533\n\nâ€¦studies use a cross-validation approach, in which one chunk of a data set is reserved for training and another for testing. This can lead to issues such as overfitting, meaning that an algorithm performs well on data similar to the information that the model has encountered before but does poorly on disparate data. â€œThe problem with cross-validation is that it tends to provide fairly optimistic results,â€ Madabhushi explains. â€œThe cleanest and best way to validate these models is through external, independent validation, where the external test set is separate and distinct from the training set and ideally from a separate institution.â€\n\nNature. 2025. PMID: 40410341\n\nTrained immunity in alveolar macrophages can lead to damaging lung inflammation, confirming the importance of context in this phenomenon.\n\neLife. 2025. doi: 10.7554/eLife.107787\n\nWhether itâ€™s a sales skill, writing skill, musical talent, preaching ability, inventiveness, food production, cleaning, or childcare, these are all value-creation skills. Few people possess all these skills, and no one is the worldâ€™s best at all of them. Thatâ€™s why most people specialize and outsource the rest.\n\nIsrael Kloss on LinkedIn\n\nActually you have 22 pairs of chromosomes numbered 1 through 22, and if youâ€™re a woman, you have a pair of X chromosomes, for a total of 23 pairs. If youâ€™re a man, you have one X and one Y chromosome instead of two Xâ€™s, so the 23rd â€œpairâ€ isnâ€™t technically a pair at all, even though some parts of Y are identical to some parts of X.\n\nSteven Salzberg on Substack"
  },
  {
    "objectID": "posts/maybe_good_sentences/index.html#section",
    "href": "posts/maybe_good_sentences/index.html#section",
    "title": "Some good sentences",
    "section": "",
    "text": "Antibody function is governed not only by antigen specificity, conferred by the antigen-binding (Fab) domain to neutralize pathogens but also by the antibody constant (Fc) domain, which recruits complement and engages Fc receptors (FcRs) on the surface of immune cells.\n\nImmunity. 2025. PMID: 40449485\n\nAny given MHC molecule can bind numerous different peptides, and some peptide can bind to several different MHC molecules. Because of this broad specificity, the binding between a peptide and an MHC molecule is often referred to as â€œpromiscuousâ€.\n\nKuby immunology 2018 p533\n\nâ€¦studies use a cross-validation approach, in which one chunk of a data set is reserved for training and another for testing. This can lead to issues such as overfitting, meaning that an algorithm performs well on data similar to the information that the model has encountered before but does poorly on disparate data. â€œThe problem with cross-validation is that it tends to provide fairly optimistic results,â€ Madabhushi explains. â€œThe cleanest and best way to validate these models is through external, independent validation, where the external test set is separate and distinct from the training set and ideally from a separate institution.â€\n\nNature. 2025. PMID: 40410341\n\nTrained immunity in alveolar macrophages can lead to damaging lung inflammation, confirming the importance of context in this phenomenon.\n\neLife. 2025. doi: 10.7554/eLife.107787\n\nWhether itâ€™s a sales skill, writing skill, musical talent, preaching ability, inventiveness, food production, cleaning, or childcare, these are all value-creation skills. Few people possess all these skills, and no one is the worldâ€™s best at all of them. Thatâ€™s why most people specialize and outsource the rest.\n\nIsrael Kloss on LinkedIn\n\nActually you have 22 pairs of chromosomes numbered 1 through 22, and if youâ€™re a woman, you have a pair of X chromosomes, for a total of 23 pairs. If youâ€™re a man, you have one X and one Y chromosome instead of two Xâ€™s, so the 23rd â€œpairâ€ isnâ€™t technically a pair at all, even though some parts of Y are identical to some parts of X.\n\nSteven Salzberg on Substack"
  },
  {
    "objectID": "cv.html",
    "href": "cv.html",
    "title": "1. åŸºæœ¬ä¿¡æ¯/background",
    "section": "",
    "text": "1. åŸºæœ¬ä¿¡æ¯/background\nå§“åï¼šå´åº·\næœ€é«˜å­¦å†ï¼šåšå£«\næ°‘æ—ï¼šæ±‰\né‚®ç®±ï¼šwu__kang@126.com\nå©šå§»ï¼šå·²å©š\nORCIDï¼š0000-0002-9024-795X\nä¸ªäººç½‘é¡µï¼šhttps://iamhealthy.github.io/\n\n\n2. æ•™è‚²/education\n\n\n2007/09 â€“ 2012/07ï¼Œä¸Šæµ·äº¤é€šå¤§å­¦ï¼Œç”Ÿç‰©åŒ–å­¦ä¸åˆ†å­ç”Ÿç‰©å­¦(åšå£«)\n\n\n2001/09 â€“ 2007/07ï¼Œè¥¿åŒ—å†œæ—ç§‘æŠ€å¤§å­¦ï¼Œç”Ÿç‰©æŠ€æœ¯(æœ¬ç¡•è¿è¯»)\n\n\n\n\n3. å·¥ä½œ/experience\n\n3.4 2022/07 - è‡³ä»Šï¼Œä¸Šæµ·é”èµ›å¾ªç›Šç”Ÿç‰©æŠ€æœ¯æœ‰é™å…¬å¸ï¼Œç§‘åˆ›ä¸­å¿ƒ(é«˜çº§å¼€å‘æ€»ç›‘)\n\n\nè‚¿ç˜¤åˆ†å­è¯Šæ–­äº§å“å¼€å‘(ç›¸å…³ä¸“åˆ©ç”³è¯·å·ï¼š202410274764.3ã€202410372505.4)ã€‚\n\n\nåŸºäºNGSçš„è¯Šæ–­æŠ€æœ¯å’Œäº§å“å¼€å‘(ç›¸å…³ä¸“åˆ©æˆæƒå…¬å‘Šå·ï¼šCN117343999Bã€CN117701691B)ã€‚\n\n\nDCsç–«è‹—ä¸´åºŠè¯•éªŒå’Œåº”ç”¨æ”¯æŒã€é—´å……è´¨å¹²ç»†èƒå¤–æ³Œä½“ä¸´åºŠè¯•éªŒå’Œåº”ç”¨æ”¯æŒã€‚\n\n\nè‚¿ç˜¤panel NGSæ•°æ®çš„ç”Ÿä¿¡åˆ†æï¼Œå‘ç°åŸºå› /è›‹ç™½çªå˜ä»¥æŒ‡å¯¼ä¸´åºŠä¸ªä½“åŒ–ç”¨è¯ã€‚\n\n\nä¸´åºŠç›¸å…³æ•°æ®çš„ç”Ÿä¿¡åˆ†æå’Œæ”¯æŒã€‚\n\n\n\n\n3.3 2021/08 â€“ 2022/06ï¼Œæ­å·æ°æ¯…ç”Ÿç‰©æŠ€æœ¯æœ‰é™å…¬å¸ï¼Œåˆ›æ–°åº”ç”¨ç ”ç©¶é™¢(åŒ»å­¦ç§‘å­¦å®¶)\n\n\nåŸºäºå…¬å¸çš„mNGSäº§å“å’Œä¸´åºŠåŒ»ç”Ÿ/ç§‘å®¤å¼€å±•åˆä½œé¡¹ç›®ï¼Œå‚ä¸å¹¶æŒ‡å¯¼ç›¸å…³é¡¹ç›®ä¹¦æ’°å†™ã€é¡¹ç›®æ¨è¿›ã€é¡¹ç›®ç»“é¢˜(æ¯”å¦‚æ•°æ®æ•´ç†ã€åˆ†æï¼ŒSCIæ–‡ç« æ’°å†™)ã€‚\n\n\n\n\n3.2 2021/06 â€“ 2021/08ï¼Œä¸Šæµ·æ´¾æ£®è¯ºç”Ÿç‰©ç§‘æŠ€æœ‰é™å…¬å¸ï¼Œç ”å‘ä¸­å¿ƒ(ç ”å‘é¡¹ç›®ç»ç†)\n\n\nè´Ÿè´£åœ¨å…¬å¸å»ºç«‹metagenomic next-generation sequencing (mNGS)è¯Šæ–­æŠ€æœ¯ã€‚çŸ­æš‚çš„3ä¸ªæœˆå·¥ä½œæœŸé—´ï¼Œå¸¦é¢†3ä¸ªäººçš„å›¢é˜Ÿå»ºç«‹äº†è¯¥æŠ€æœ¯çš„å®éªŒéƒ¨åˆ†ï¼ŒåŠç”Ÿä¿¡åˆ†æçš„æ¡†æ¶ã€‚\n\n\n\n\n3.1 2012/07 â€“ 2021/06ï¼Œå¤æ—¦å¤§å­¦é™„å±ä¸Šæµ·å¸‚å…¬å…±å«ç”Ÿä¸´åºŠä¸­å¿ƒï¼Œç§‘å­¦ç ”ç©¶éƒ¨(åŠ©ç†ç ”ç©¶å‘˜)\n\n\nå®¿ä¸»(å¿—æ„¿è€…å¤–å‘¨è¡€ã€åå™¬ç»†èƒ)å¯¹äºç»“æ ¸åˆ†ææ†èŒçš„(å…¨åŸºå› ç»„)è½¬å½•åº”ç­”å’Œç”Ÿä¿¡åˆ†æ(ç›¸å…³ä¸“åˆ©æˆæƒå…¬å‘Šå·ï¼šCN104182654B)ã€‚\n\n\nç‰›åˆ†ææ†èŒå¡ä»‹è‹—(ç»“æ ¸ç–«è‹—)çš„åŸºå› é‡ç»„æ”¹é€ ï¼ŒåŠåœ¨å°é¼ çš„å…ç–«ä¿æŠ¤ç ”ç©¶(ç›¸å…³ä¸“åˆ©æˆæƒå…¬å‘Šå·ï¼šCN111979162Bã€CN106148258B)ã€‚\n\n\nç™½è¡€ç—…å‘ç—…æœºç†æ¢ç´¢(åˆ†å­å’Œç»†èƒå±‚é¢)(ç›¸å…³ä¸“åˆ©æˆæƒå…¬å‘Šå·ï¼šCN103740760B)ã€‚\n\n\n\n\n\n4. æœŸåˆŠè®ºæ–‡/journal articles\n\n4.1 (å¹¶åˆ—)ä¸€ä½œ/(co-)1st author SCI (# co-first authorï¼Œ*corresponding author)\n\n\nXu JC#, Wu K#, Ma RQ, Li JH, Tao J, Hu ZD, Fan XY*. Establishment of an in vitro model of monocyte-like THP-1 cells for trained immunity induced by bacillus Calmette-GuÃ©rin. BMC Microbiol. 2024;24:130. (IF: 4.2)\n\n\nShi JC#, Wu WJ#, Wu K#, Ni CR, He GQ, Zheng SL, Cheng F, Yi YX, Ren RT*, Jiang XG*. The diagnosis of leptospirosis complicated by pulmonary tuberculosis complemented by metagenomic next-generation sequencing: a case report. Front Cell Infect Microbiol. 2022;12:922996. (Case report). (IF: 5.7)\n\n\nLiu C#, Wu K#, Sun TY, Chen B, Yi YX, Ren RT*, Xie LX*, Xiao K*. Effect of invasive mechanical ventilation on the diversity of the pulmonary microbiota. Crit Care. 2022;26:252. (Review). (IF: 15.1)\n\n\nWu K, Yan B, Douglas BL, Li T*, Fan XY*. Tailored co-localization analysis of intracellular microbes and punctum-distributed phagosome-lysosome pathway proteins using ImageJ plugin EzColocalization. Sci Rep. 2021;11:1096. (IF: 4.996)\n\n\nWu K, Li M, Chen ZY, Douglas BL*, Fan XY*. Probe signal values in mRNA arrays imply an excessive involvement of neutrophil FCGR1 in tuberculosis. Front Med. 2020;7:19. (IF: 5.091)\n\n\nPei ZL#, Wu K#, Li ZH#, Li CQ#, Zeng L, Li F, Pei N, Liu HM, Zhang SL, Song YZ, Zhang XY, Xu JQ, Fan XY*, Wang J*. Pharmacologic ascorbate as a pro-drug for hydrogen peroxide release to kill mycobacteria. Biomed Pharmacother. 2019;109:2119-2127. (IF: 4.545)\n\n\nWu K#, Wong KW#, Deng WL, Zhang H, Li J, Lowrie DB*, Fan XY*. The numerical predominance and large transcriptome differences of neutrophils in peripheral blood together inevitably account for a reported pulmonary tuberculosis signature. Int J Genomics. 2017;2017:5830971. (IF: 1.904)\n\n\nWu K#, Zhao XJ#, Wong KW, Fan XY*. Comparison of plasmid DNA versus PCR amplified gene of insert DNA for nucleofection in Kasumi-1 cells. Cytotechnology. 2015;67(2):275-283. (IF: 1.864)\n\n\nWu K, Fang H, Lyu LD, Lowrie DB, Wong KW*, Fan XY*. A derived network-based interferon-related signature of human macrophages responding to Mycobacterium tuberculosis. Biomed Res Int. 2014;2014:713071. (IF: 1.579)\n\n\nMa H#, Wu K#, Liu F Yang H, Kang H, Chen NN, Yuan Q, Zhou WJ, Fan XY*. Dose of incorporated immunodominant antigen in recombinant BCG impacts modestly on Th1 immune response and protective efficiency against Mycobacterium tuberculosis in mice. J Immunol Res. 2014;2014:196124. (IF: 2.934)\n\n\nJin W#, Wu K#, Li YZ# Yang WT, Zou B, Zhang F, Zhang J*, Wang KK*. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia. Oncogene. 2013;32(15):1978-1987. (IF: 8.559)\n\n\nWu K#, Dong DD#, Fang H#, Levillain F#, Jin W, Mei J, Gicquel B, Du Y, Wang K, Gao Q, Neyrolles O*, Zhang J*. An interferon-related signature in the transcriptional core response of human macrophages to Mycobacterium tuberculosis infection. PLoS One. 2012;7(6):e38367. (IF: 3.730)\n\n\näº¦å¯é€šè¿‡My Bibliography (NCBI)æŸ¥çœ‹å¦‚ä¸Šåˆ—è¡¨ï¼šhttps://www.ncbi.nlm.nih.gov/myncbi/1xKGynflhNK5t/bibliography/public/\n\n\n\n\n4.2 (å¹¶åˆ—)ä¸€ä½œä¸­æ–‡/(co-)1st author Chinese (# co-first authorï¼Œ*corresponding author)\n\n\nå´åº·#ã€å±ˆè“‰#ã€ç‹åˆšã€è–›æ¸…åã€å•å»ºæ–°ã€Douglas B. Lowrieã€èŒƒå°å‹‡*ã€‚åŸºäºå¸¸è§„å¼•ç‰©é¶å‘ç»“æ ¸åˆ†ææ†èŒIIå‹åˆ†ææ†èŒæ•£åœ¨é‡å¤å•ä½çš„æ’æ¸©æ‰©å¢ã€‚å¤æ—¦å­¦æŠ¥(åŒ»å­¦ç‰ˆ)ã€‚2020;47:799-808ã€‚\n\n\n\n\n4.3 ä¸€ä¸ªæœ‰æ„æ€çš„æ–‡ç¨¿/one interesting draft\n\n\nå´åº·ã€‚ã€Šçº¢æ¥¼æ¢¦ã€‹ä¸­çš„ç–‘ä¼¼æ´»åŠ¨æ€§ç»“æ ¸ç—…æ‚£è€…ã€‚çŸ¥ä¹ (https://zhuanlan.zhihu.com/p/148348007)ã€‚2020ã€‚\n\n\n\n\n4.4 é(å¹¶åˆ—)ä¸€ä½œæ–‡ç« /non-(co-)1st articles (# co-first authorï¼Œ*corresponding author)\n\n\nHuang Z#, Huang H#, Hu J, Xia L, Liu XH, Qu R, Huang XL, Yang Y, Wu K, Ma RQ, Xu JC, Chen ZY, Wu YH, Yang J, Fang Y, Zeng JF, Lai WH, Sui GD, Sha W, Xiong YH, Lu SH*, Fan XY*. A novel quantitative urine LAM strip for point-of-care tuberculosis diagnosis in non-HIV adults. J Infect. 2023;S0163-4453(23)00586-8. (Letter).\n\n\nHuang H#, Qu R#, Wu K, Xu JC, Li JH, Lu SH, Sui GD, Fan XY*. Proteinase K-pretreated ConA-based ELISA assay: a novel urine LAM detection strategy for TB diagnosis. Front Microbiol. 2023;14:1236599.\n\n\nå±ˆè“‰ã€å´åº·ã€å´å¨Ÿã€èŒƒå°å‹‡ã€å•å»ºæ–°*ã€‚ç»“æ ¸åˆ†ææ†èŒæ—©æœŸåˆ†æ³Œè›‹ç™½MPT64çš„åŸæ ¸è¡¨è¾¾åŠå…¶åœ¨ç»“æ ¸ç—…è¡€æ¸…å­¦è¯Šæ–­ä¸Šçš„åˆæ­¥åº”ç”¨ã€‚ä¸­å›½ç”Ÿç‰©åˆ¶å“å­¦æ‚å¿—ã€‚2021:34(05):566-570ã€‚\n\n\nZhao HM#, Du R#, Li CL, Ji P, Li HC, Wu K, Hu ZD, Lu SH, Douglas BL, Fan XY*. Differential T cell responses against DosR-associated antigen Rv2028c in BCG-vaccinated populations with tuberculosis infection. J Infect. 2019;78(4):275-280.\n\n\nHu ZD#, Wong KW#, Zhao HM, Wen HL, Ji P, Ma H, Wu K, Lu SH, Li F, Li ZM, Shu T, Xu JQ, Douglas BL, Fan XY*. Sendai virus mucosal vaccination establishes lung-resident memory CD8 T cell immunity and boosts BCG-primed protection against TB in mice. Mol Ther. 2017;25(5):1222-1233.\n\n\nWen HL, Li CL, Li G, Lu YH, Li HC, Li T, Zhao HM, Wu K, Douglas BL, Lv JX, Lu SH*, Fan XY*. Involvement of methylated HBHA expressed from Mycobacterium smegmatis in an IFN-Î³ release assay to aid discrimination between latent infection and active tuberculosis in BCG-vaccinated populations. Eur J Clin Microbiol Infect Dis. 2017;36(8):1415-1423.\n\n\nLi G#, Li F#, Zhao HM, Wen HL, Li HC, Li CL, Ji P, Xu P, Wu K, Hu ZD, Lu SH, Douglas BL, Lv JX*, Fan XY*. Evaluation of a new IFN-Î³ release assay for rapid diagnosis of active tuberculosis in a high-incidence setting. Front Cell Infect Microbiol. 2017;7:117.\n\n\nææ˜¥ç²ã€å´åº·ã€èŒƒå°å‹‡*ã€‚æ°§åŒ–åº”æ¿€ä¸ç»“æ ¸ç—…ã€‚ç”Ÿå‘½ç§‘å­¦ã€‚2017;29(11):1108-1112ã€‚(ç»¼è¿°)ã€‚\n\n\né—®å¯’åˆ©ã€ææµ·èªã€ææ ¹ã€èµµæ…§æ•ã€æ–½ç†æ•ã€éŸ©ä¼Ÿé–ã€å´åº·ã€èŒƒå°å‹‡*ã€‚ç»“æ ¸åˆ†ææ†èŒè‚ç´ ç»“åˆè¡€å‡é»é™„ç´ çš„åŸæ ¸è¡¨è¾¾åŠå…¶åœ¨ç»“æ ¸ç—…è¡€æ¸…å­¦è¯Šæ–­ä¸­çš„åº”ç”¨ã€‚ä¸­å›½ç”Ÿç‰©åˆ¶å“å­¦æ‚å¿—ã€‚2016;29(05):497-502ã€‚\n\n\nChen L, Guo S, Wu LX, Fan XY, Ma H, Wu K, Wu J, Zhang JH*. IL-17A Autoantibody Induced by Recombinant Mycobacterium smegmatis Expressing Ag85A-IL-17A Fusion Protein. Appl Biochem Biotechnol. 2015; 176(7):2018-2026.\n\n\nå‰èã€èŒƒå°å‹‡*ã€å´åº·ã€å¢æ°´åã€‚ç»“æ ¸åˆ†ææ†èŒæ½œä¼æ€§æ„ŸæŸ“ç›¸å…³æŠ—åŸçš„ç ”ç©¶è¿›å±•ã€‚ä¸­åå¾®ç”Ÿç‰©å­¦å’Œå…ç–«å­¦æ‚å¿—ã€‚2015;35(1):59-64ã€‚(ç»¼è¿°)ã€‚\n\n\nKang H, Yuan Q, Ma H, Hu ZD, Han DP, Wu K, Douglas BL, Fan XY*. Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination. Immunology. 2014;143(4):661-669.\n\n\n\n\n4.5 æ”¾å¼ƒå‘è¡¨çš„ä¸€ä½œæ–‡ç« /1st author articles abandoned for publication (# co-first authorï¼Œ*corresponding author)\n\n\nWu K, Douglas BL*, Fan XY*. Fever of unknown origin and incipient tuberculosis. Un-published. Drafted in 2020. (Letter).\n\n\nWu K, Douglas BL, Wong KW*, Fan XY*. Re-analysis of the transcriptome data of host Macrophages in response to Mycobacterium tuberculosis infection by weighted gene co-expression network analysis. Un-published. Drafted in 2014.\n\n\nè‹¥æ„Ÿå…´è¶£ï¼Œå¯åˆ†äº«ã€‚\n\n\n\n\n4.6 è¢«è‡´è°¢çš„æ–‡ç« /acknowledged articles(# co-first authorï¼Œ*corresponding author)\n\n\nCheng XB#, Chai RR#, Zhang T#, Chen YJ, Fan FQ, Ye YF, Jin GQ, Li TT, Wang H, Ding JW, Zheng M, Han YH, Tang QZ, Song ZQ, Ji YQ, Song WW, Luo WF*, Kang Y*. A novel methylation-detection panel for HPV associated high-grade squamous intraepithelial lesion and cervical cancer screening. Sci Rep. 2024;14(1):25556. â€œIn particular, we acknowledge Dr.Â Wu Kang for giving professional advice on this article.â€\n\n\n\n\n\n5. ä¸“åˆ©/patents\n\n\nå¼ è…¾ã€å´åº·ã€çºªé€¸ç¾¤ã€ä¸œäºšå¨Ÿã€é’Ÿå†›ã€ç½—å«å³°ã€èŒƒå°å‹‡ã€èµµå»ºåã€‚ä¸€ç§æ”¹å˜ä¸åŒæ ¸é…¸é¶æ ‡ç›¸å¯¹PCRæ‰©å¢é€Ÿåº¦çš„æ–¹æ³•ã€‚å‘æ˜ä¸“åˆ©ã€‚ç”³è¯·å·ï¼š202410372505.4ã€‚ç”³è¯·æ—¥æœŸï¼š2024.03.29ã€‚è¯¥ä¸“åˆ©åœ¨2024.06.18è¢«é©³å›ã€‚æœ¬äººè‡ªè®¤ä¸ºè¯¥ä¸“åˆ©æœ‰æœ‰è¶£çš„å‘ç°ï¼Œå³é€šè¿‡å…·ä½“å®éªŒè¯å®äº†å¸¦æœ‰é€šç”¨å¼•ç‰©åºåˆ—çš„é¶æ ‡ç‰¹å¼‚å¼•ç‰©å¯¹çš„qPCRæ‰©å¢æ€§èƒ½æ›´å¥½ï¼ˆæ‰©å¢ä½“ç³»äº¦åŒ…æ‹¬é€šç”¨å¼•ç‰©å¯¹ã€‚ç›¸æ¯”äºæœªå¸¦é€šç”¨å¼•ç‰©åºåˆ—çš„é¶æ ‡ç‰¹å¼‚å¼•ç‰©å¯¹çš„qPCRï¼‰ï¼Œè¿›è€Œèƒ½å¤Ÿè¾ƒå¥½å®ç°æ”¹å˜ä¸åŒæ ¸é…¸é¶æ ‡çš„ç›¸å¯¹PCRæ‰©å¢é€Ÿåº¦çš„ç›®çš„ã€‚\n\n\nå´åº·ã€å¼ è…¾ã€çºªé€¸ç¾¤ã€é’Ÿå†›ã€ç½—å«å³°ã€èŒƒå°å‹‡ã€èµµå»ºåã€‚ä¸€ç§é€šè¿‡é¢„å…ˆPCRæ”¹å˜ä¸åŒæ ¸é…¸é¶æ ‡ç›¸å¯¹æ‰©å¢é€Ÿåº¦çš„æ–¹æ³•ã€‚å‘æ˜ä¸“åˆ©ã€‚ç”³è¯·å·ï¼š202410274764.3ã€‚ç”³è¯·æ—¥æœŸï¼š2024.03.11ã€‚\n\n\nå´åº·ã€èµµå»ºåã€å¼ è…¾ã€èŒƒå°å‹‡ã€ç½—å«å³°ã€ä¸œäºšå¨Ÿã€çºªé€¸ç¾¤ã€‚åŸºäºäººåŸºå› ç»„æ‰©å¢å­çš„ illumina æµ‹åºæ–‡åº“æ„å»ºçš„å¼•ç‰©ç»„åˆã€‚å‘æ˜ä¸“åˆ©ã€‚æˆæƒå…¬å‘Šå·ï¼šCN117701691Bã€‚ç”³è¯·æ—¥æœŸï¼š2024.02.01ã€‚\n\n\nå´åº·ã€ä¸œäºšå¨Ÿã€å¼ è…¾ã€èŒƒå°å‹‡ã€ç½—å«å³°ã€èµµå»ºåã€çºªé€¸ç¾¤ã€‚åŸºäºå·¦ä¾§æ¢é’ˆé€€ç«å’Œå³ä¾§æ¢é’ˆé€€ç«å»¶ä¼¸çš„æ ¸é…¸æ‰©å¢æ–¹æ³•ã€‚å‘æ˜ä¸“åˆ©ã€‚æˆæƒå…¬å‘Šå·ï¼šCN117343999Bã€‚ç”³è¯·æ—¥æœŸï¼š2023.12.05ã€‚\n\n\nèŒƒå°å‹‡ã€å´åº·ã€ç½—é“è‰¯ã€‚åŸºäºå¸¸è§„å¼•ç‰©çš„é’ˆå¯¹ä¸²è”é‡å¤åºåˆ—çš„æ’æ¸©æ‰©å¢ä½“ç³»ã€æ‰©å¢æ–¹æ³•åŠå¸¸è§„å¼•ç‰©å¯¹ã€‚å‘æ˜ä¸“åˆ©ã€‚æˆæƒå…¬å‘Šå·ï¼šCN111269969Bï¼›ç”³è¯·æ—¥æœŸï¼š2020.03.06ã€‚\n\n\nèŒƒå°å‹‡ã€å´åº·ã€ç½—é“è‰¯ã€‚é‡ç»„å¡ä»‹è‹—èŒæ ªã€å…¶åˆ¶å¤‡æ–¹æ³•å’Œç”¨é€”ã€‚å‘æ˜ä¸“åˆ©ã€‚æˆæƒå…¬å‘Šå·ï¼šCN111979162Bï¼›ç”³è¯·æ—¥æœŸï¼š2019.05.22ã€‚\n\n\nèŒƒå°å‹‡ã€å•äº®ä¸œã€èµµå›½å±ã€é©¬è¾‰ã€å´åº·ã€‚mazGåŸºå› ç¼ºå¤±çš„æŠ—ç»“æ ¸é‡ç»„å¡ä»‹è‹—ã€‚å‘æ˜ä¸“åˆ©ã€‚æˆæƒå…¬å‘Šå·ï¼šCN106148258Bï¼›ç”³è¯·æ—¥æœŸï¼š2015.04.20ã€‚\n\n\nå´åº·ã€é»„å®¶é¢–ã€èŒƒå°å‹‡ã€‚åŸºäºè›‹ç™½-è›‹ç™½ç›¸äº’ä½œç”¨ç½‘ç»œçš„åŸºå› é›†é‰´å®šæ–¹æ³•ã€‚å‘æ˜ä¸“åˆ©ã€‚æˆæƒå…¬å‘Šå·ï¼šCN104182654Bï¼›ç”³è¯·æ—¥æœŸï¼š2014.07.30ã€‚\n\n\nå´åº·ã€èŒƒå°å‹‡ã€é»„å®¶é¢–ã€èµµæ—­æ°ã€‚PCRæ‰©å¢åŸºå› æ ¸è½¬æ‚¬æµ®åŠ¨ç‰©ç»†èƒçš„æ–¹æ³•ã€‚å‘æ˜ä¸“åˆ©ã€‚æˆæƒå…¬å‘Šå·ï¼šCN103740760Bï¼›ç”³è¯·æ—¥æœŸï¼š2014.01.09ã€‚ä¸“åˆ©æƒç»ˆæ­¢æ—¥æœŸï¼š2024.01.09ã€‚\n\n\n\n\n6. ç§‘ç ”é¡¹ç›®/scientific projects\n\n\n\n\n\n\n\n\n\n\n\n\nåºå·\né¡¹ç›®ç±»å‹\né¡¹ç›®åç§°\né¡¹ç›®å·\nè´Ÿè´£äºº\næœŸé™\nç»è´¹é¢(ä¸‡)\n\n\n\n\n5\nèˆŸå±±å¸‚æ™®é™€åŒºä¸€èˆ¬ç§‘æŠ€è®¡åˆ’é¡¹ç›®\nåŸºäºé¶å‘é«˜é€šé‡æµ‹åºçš„è†€èƒ±ç™Œå’Œæ³Œå°¿æ„ŸæŸ“é›†æˆè¯Šæ–­çš„æŠ€æœ¯å’Œäº§å“ç ”å‘\n2023YB003\nå´åº·\n2023/01-2025/06\n20\n\n\n4\nä¸Šæµ·å¸‚ç§‘å§”åŒ»å­¦å¼•å¯¼\nç»“æ ¸åˆ†ææ†èŒDosRæŠ—åŸåœ¨ç»“æ ¸ç—…å…ç–«é‰´åˆ«è¯Šæ–­åŠä¸´åºŠé¢„åä¸­çš„åº”ç”¨ç ”ç©¶\n18411970700\nå´åº·\n2018/09-2021/09\n20\n\n\n3\nå›½å®¶é‡ç‚¹ç ”å‘è®¡åˆ’\nç§ç•œåœºç‰›ç»“æ ¸å’Œå¸ƒé²æ°èŒç—…ç»¼åˆé˜²æ§ä¸å‡€åŒ–æŠ€æœ¯é›†æˆä¸ç¤ºèŒƒâ€“&gt;è¯¾é¢˜2ï¼šç‰›ç»“æ ¸è¯Šæ–­æŠ€æœ¯é›†æˆä¸å‡€åŒ–ç¤ºèŒƒâ€“&gt;å­è¯¾é¢˜3ï¼šåŸºäºå¾®æµæ§èŠ¯ç‰‡çš„ç‰›ç»“æ ¸æŠ—åŸå¿«é€Ÿæ£€æµ‹äº§å“çš„ç ”å‘\n2018YFD0500900\nå´åº·(å­è¯¾é¢˜3)\n2018/06-2021/09\n47/1263\n\n\n2\nå›½è‡ªç„¶é’å¹´\nç»“æ ¸åˆ†ææ†èŒèƒå†…è¡¨è¾¾ä¸Šè°ƒåˆ†æ³Œæ€§åŸºå› é›†çš„Tç»†èƒæŠ—åŸç­›é€‰åŠå…¶å…ç–«ä¿æŠ¤åŠŸèƒ½é‰´å®š\n81301407\nå´åº·\n2014/01-2016/12\n23\n\n\n1\nä¸Šæµ·å¸‚ç§‘å§”é’å¹´\nActAä¿ƒè¿›åˆ†ææ†èŒè‡ªå™¬é€ƒé€¸å¹¶æé«˜å¡ä»‹è‹—MHC Iç±»æŠ—åŸå‘ˆé€’çš„ç ”ç©¶\n12ZR1448200\nå´åº·\n2012/10-2015/09\n10\n\n\n\n\n\n7. äººæ‰é¡¹ç›®/talent projects\n\n\n\n\n\n\n\n\n\n\n\nåºå·\né¡¹ç›®åç§°\né¡¹ç›®å·\nè´Ÿè´£äºº\næœŸé™\nç»è´¹é¢(ä¸‡)\n\n\n\n\n1\nèˆŸå±±å¸‚â€œèˆŸåˆ›æœªæ¥â€æµ·çº³è®¡åˆ’åˆ›æ–°é•¿æœŸäººæ‰ II ç±»\nã€2023ã€‘ç¬¬ 1 æ‰¹-08\nå´åº·\n2024/04-2029/04\n30"
  },
  {
    "objectID": "contact.html",
    "href": "contact.html",
    "title": "Contact",
    "section": "",
    "text": "Phone: +86-15821314790\nEmail_1: wu__kang@126.com\nEmail_2: wukangx9@gmail.com\nEmail_3: 15821314790@126.com\nWechat: +86-15821314790, or scan the following QR code:"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Kang Wu/å´åº·",
    "section": "",
    "text": "I completed both my Bachelorâ€™s and Masterâ€™s degrees in Biotechnology through a combined program/æœ¬ç¡•è¿è¯» at Northwest A&F University, followed by a Ph.D.Â in Biochemistry and Molecular Biology from Shanghai Jiao Tong University. From 2012 to 2021, I worked as a Research Assistant at Shanghai Public Health Clinical Center (affiliated with Fudan University), focusing on tuberculosis immunology, vaccine development, and bioinformatics.\nAfter transitioning from academia to industry, I have continued to pursue advancements in omics- and cell-relevant technologies, particularly in therapeutic and diagnostic applications. I trust that I can follow in the footsteps of individuals like 2024 Nobel Prize laureate John M. Jumper, who made an impressive transition to industry after his Ph.D.Â graduationğŸ˜€.\nI am self-taught in R and am continually enhancing my bioinformatics skills, including Bash and Python (my hobby tooğŸ˜€).\nYou can view myğŸ’©(co-)first author articles, and the research projects Iâ€™ve led, from my â€œORCIDâ€. MyğŸ’©full resumÃ©, a mix of Chinese and English, is available from the â€œResumÃ©â€."
  },
  {
    "objectID": "posts/To-present_bio-miscellany_Q-and-A/index.html",
    "href": "posts/To-present_bio-miscellany_Q-and-A/index.html",
    "title": "The biological-relevant questions",
    "section": "",
    "text": "A1: You can check out this website: International Committee on Taxonomy of Viruses: ICTV."
  },
  {
    "objectID": "posts/To-present_bio-miscellany_Q-and-A/index.html#q1-is-there-a-website-where-we-can-check-whether-a-virus-is-a-dna-or-rna-virus-and-beyond",
    "href": "posts/To-present_bio-miscellany_Q-and-A/index.html#q1-is-there-a-website-where-we-can-check-whether-a-virus-is-a-dna-or-rna-virus-and-beyond",
    "title": "The biological-relevant questions",
    "section": "",
    "text": "A1: You can check out this website: International Committee on Taxonomy of Viruses: ICTV."
  },
  {
    "objectID": "posts/To-present_bio-miscellany_Q-and-A/index.html#q2-how-to-define-a-successful-pathogen",
    "href": "posts/To-present_bio-miscellany_Q-and-A/index.html#q2-how-to-define-a-successful-pathogen",
    "title": "The biological-relevant questions",
    "section": "Q2: How to define a successful pathogen?",
    "text": "Q2: How to define a successful pathogen?\nA2:\n\nAlthough the definition of a successful pathogen can be uncertain and controversial, in recent years, this term has been used to define those microorganisms that manage to establish a successful relationship with their host, which guarantees its transmissibility and its permanence on Earth. Thus, the ability of a microorganism to rapidly adapt to changes in the microenvironment through the deployment of specialized strategies, and survive within its host despite the deadly attack of the innate and adaptive immune response seems to be the key leading to evolutionary success.\n\n\nC. glabrata (å…‰æ»‘å¿µç èŒï¼ŒçœŸèŒ) is a successful pathogen and an artist manipulating the immune response like M. tuberculosis (ç»“æ ¸åˆ†ææ†èŒï¼Œç»†èŒ).\n\nMicrobiol Res. 2022. PMID: 35430489\nThen, how to define a successful person?"
  },
  {
    "objectID": "posts/To-present_bio-miscellany_Q-and-A/index.html#q3-how-long-can-mycobacterium-tuberculosis-hold-its-breath",
    "href": "posts/To-present_bio-miscellany_Q-and-A/index.html#q3-how-long-can-mycobacterium-tuberculosis-hold-its-breath",
    "title": "The biological-relevant questions",
    "section": "Q3: How long can Mycobacterium tuberculosis â€œhold its breathâ€?",
    "text": "Q3: How long can Mycobacterium tuberculosis â€œhold its breathâ€?\nA3:\n\nFor example, Corper and Cohn, showed that sealed Mtb cultures held at 37Â°C for 12-30 years yielded viable bacilli in their anaerobic sediments.\n\nAm J Respir Crit Care Med. 2022. PMID: 35442854"
  },
  {
    "objectID": "posts/To-present_bio-miscellany_Q-and-A/index.html#q4-how-long-ago-was-the-first-case-of-tuberculosis-tb-discovered",
    "href": "posts/To-present_bio-miscellany_Q-and-A/index.html#q4-how-long-ago-was-the-first-case-of-tuberculosis-tb-discovered",
    "title": "The biological-relevant questions",
    "section": "Q4: How long ago was the first case of tuberculosis (TB) discovered?",
    "text": "Q4: How long ago was the first case of tuberculosis (TB) discovered?\nA4:\n\nTuberculosis has been a scourge of humanity for millennia: the oldest known cases are in a pair of 9,000-year-old skeletons.\n\nNature. 2022. PMID: 35534687"
  },
  {
    "objectID": "posts/To-present_bio-miscellany_Q-and-A/index.html#q5-what-are-the-historical-vaccination-policies-for-the-bcg-tuberculosis-vaccine-in-various-countries",
    "href": "posts/To-present_bio-miscellany_Q-and-A/index.html#q5-what-are-the-historical-vaccination-policies-for-the-bcg-tuberculosis-vaccine-in-various-countries",
    "title": "The biological-relevant questions",
    "section": "Q5: What are the historical vaccination policies for the BCG tuberculosis vaccine in various countries?",
    "text": "Q5: What are the historical vaccination policies for the BCG tuberculosis vaccine in various countries?\nA5: Visit THE BCG WORLD ATLAS.\nPLoS Med. 2011. PMID: 21445325"
  }
]